Literature DB >> 28753464

Mortality and the relationship of somatic comorbidities to mortality in schizophrenia. A nationwide matched-cohort study.

I Bitter1, P Czobor2, A Borsi3, L Fehér3, B Z Nagy3, M Bacskai4, P Rakonczai4, R Hegyi4, T Németh4, P Varga5, J Gimesi-Országh5, P Fadgyas-Freyler5, J Sermon6, P Takács3.   

Abstract

AIM: We conducted a matched-cohort study to assess mortality in schizophrenia and the relationship of mortality with comorbid somatic conditions and suicide attempts.
METHOD: A full-population register-based prospective matched-cohort study was performed including all eligible patients with schizophrenia in Hungary between 01/01/2005 and 31/12/2013. Control subjects were individually matched to patients with schizophrenia at a 5:1 ratio. The principal outcome measure was death due to any reason. A non-parametric approach was used for descriptive statistical purposes, the Kaplan-Meier model for survival analysis, and the Cox proportional-hazards regression model for inferential statistics.
RESULTS: Patients with schizophrenia (n=65,169) had substantially higher risk of all-cause mortality than the control subjects (n=325,435) (RR=2.4; P<0.0001). Comorbidities and suicide attempts were associated with significantly increased mortality in both groups. As compared to the controls, 20-year old males with schizophrenia had a shorter life expectancy by 11.5years, and females by 13.7years; the analogous numbers for 45-year old schizophrenics were 8.1 and 9.6years, respectively.
CONCLUSIONS: A significant mortality gap - mainly associated with somatic comorbidities - was detected between patients with schizophrenia and individually matched controls. Improved medical training to address the disparity in mortality, and many other factors including lack of resources, access to and model of medical care, lifestyle, medication side effects, smoking, stigma, need for early intervention and adequate health care organization could help to better address the physical health needs of patients with schizophrenia.
Copyright © 2017 The Author(s). Published by Elsevier Masson SAS.. All rights reserved.

Entities:  

Keywords:  Comorbidity; Mortality; Physical health; Schizophrenia; Suicide

Mesh:

Substances:

Year:  2017        PMID: 28753464     DOI: 10.1016/j.eurpsy.2017.05.022

Source DB:  PubMed          Journal:  Eur Psychiatry        ISSN: 0924-9338            Impact factor:   5.361


  17 in total

1.  20-year follow-up study of physical morbidity and mortality in relationship to antipsychotic treatment in a nationwide cohort of 62,250 patients with schizophrenia (FIN20).

Authors:  Heidi Taipale; Antti Tanskanen; Juha Mehtälä; Pia Vattulainen; Christoph U Correll; Jari Tiihonen
Journal:  World Psychiatry       Date:  2020-02       Impact factor: 49.548

2.  Mortality in people with schizophrenia: a systematic review and meta-analysis of relative risk and aggravating or attenuating factors.

Authors:  Christoph U Correll; Marco Solmi; Giovanni Croatto; Lynne Kolton Schneider; S Christy Rohani-Montez; Leanne Fairley; Nathalie Smith; István Bitter; Philip Gorwood; Heidi Taipale; Jari Tiihonen
Journal:  World Psychiatry       Date:  2022-06       Impact factor: 79.683

3.  Non-psychiatric hospitalization length-of-stay for patients with psychotic disorders: A mixed methods study.

Authors:  Guy M Weissinger; J Margo Brooks Carthon; Bridgette M Brawner
Journal:  Gen Hosp Psychiatry       Date:  2020-07-31       Impact factor: 3.238

4.  Mortality Rates After the First Diagnosis of Psychotic Disorder in Adolescents and Young Adults.

Authors:  Gregory E Simon; Christine Stewart; Bobbi Jo Yarborough; Frances Lynch; Karen J Coleman; Arne Beck; Belinda H Operskalski; Robert B Penfold; Enid M Hunkeler
Journal:  JAMA Psychiatry       Date:  2018-03-01       Impact factor: 21.596

5.  Peripheral immune markers and antipsychotic non-response in psychosis.

Authors:  Daniela Enache; Naghmeh Nikkheslat; Dina Fathalla; B Paul Morgan; Shôn Lewis; Richard Drake; Bill Deakin; James Walters; Stephen M Lawrie; Alice Egerton; James H MacCabe; Valeria Mondelli
Journal:  Schizophr Res       Date:  2021-03-02       Impact factor: 4.662

6.  Telomere length is associated with childhood trauma in patients with severe mental disorders.

Authors:  Monica Aas; Torbjørn Elvsåshagen; Lars T Westlye; Tobias Kaufmann; Lavinia Athanasiu; Srdjan Djurovic; Ingrid Melle; Dennis van der Meer; Carmen Martin-Ruiz; Nils Eiel Steen; Ingrid Agartz; Ole A Andreassen
Journal:  Transl Psychiatry       Date:  2019-03-21       Impact factor: 6.222

7.  Physical Health Literacy and Health-related Behaviors in Patients with Psychosis.

Authors:  Sung-Wan Kim; Woo-Young Park; Min Jhon; Mina Kim; Ju-Yeon Lee; Seon-Young Kim; Jae-Min Kim; Il-Seon Shin; Jin-Sang Yoon
Journal:  Clin Psychopharmacol Neurosci       Date:  2019-05-31       Impact factor: 2.582

8.  Comparative effectiveness of second generation long-acting injectable antipsychotics based on nationwide database research in Hungary.

Authors:  P Takács; P Czobor; L Fehér; J Gimesi-Országh; P Fadgyas-Freyler; M Bacskai; P Rakonczai; A Borsi; R Hegyi; T Németh; J Sermon; I Bitter
Journal:  PLoS One       Date:  2019-06-13       Impact factor: 3.240

9.  Health and work disability outcomes in parents of patients with schizophrenia associated with antipsychotic exposure by the offspring.

Authors:  Heidi Taipale; Syed Rahman; Antti Tanskanen; Juha Mehtälä; Fabian Hoti; Erik Jedenius; Dana Enkusson; Amy Leval; Jan Sermon; Jari Tiihonen; Ellenor Mittendorfer-Rutz
Journal:  Sci Rep       Date:  2020-01-27       Impact factor: 4.379

10.  Stop Turning a Blind Eye: Tobacco Smoking Among Egyptian Patients With Schizophrenia.

Authors:  Hussien Elkholy; Nahla Nagy; Ghada R A Taha; Mahmoud Elhabiby; Mostafa Yosef; Lobna Azzam
Journal:  Front Psychiatry       Date:  2019-01-04       Impact factor: 4.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.